Phase 1 Study of Weekly Anti-Vascular Endothelial Growth Factor Receptor 1 (VEGFR-1) Monoclonal Antibody IMC-18F1 in Patients With Advanced Solid Tumors Who No Longer Respond to Standard Therapy or For Whom No Standard Therapy is Available.
Phase of Trial: Phase I
Latest Information Update: 29 Sep 2010
At a glance
- Drugs Icrucumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 24 Feb 2010 Actual end date (Nov 2009) and actual number of patients (27) added as reported by ClinicalTrials.gov.
- 24 Feb 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 08 Jan 2009 Planned end date changed from Mar 2009 to Apr 2009 as reported by ClinicalTrials.gov.